Start Codon

Our fourth and final presenting portfolio company at our Innovation Showcase is Emm, the start-up whose mission is to empower individuals to change their quality of life by inherently understanding their health through technology and specialist knowledge.   Less than 2.5% of publicly funded research is dedicated solely to reproductive health, yet 1 in 3 women will suffer from a reproductive or gynaecological health problem.   Clinical baseline data is key for tracking reproductive health, but neither consumers nor clinicians have the tools to accurately measure this.   Founded by CEO, Jenny Button, Emm has built biometric technology to bring this data to the 1/3 of women with severe reproductive health symptoms. Their technology can monitor key metrics like volume, flow rate, cycle length and regularity to aid understanding of menstrual health.   To hear more about Emm's technology, or to meet with Jenny, please register your interest here: https://rb.gy/qc7bfg   #ReproductiveHealth #MenstrualHealthcare #WomensHealth #StartUp #Innovation

Our thanks to Venner Shipley for hosting our Meet the Experts START Programme event this week. Throughout the day, founders got to hear from experts on finance, legal, intellectual property, communications and commercialisation. In between sessions there was the chance to network with each other and our experts. A big Start Codon thank you to Venner Shipley, Zyme Communications Ltd, Taylor Wessing, PEM and Triple Chasm for supporting the day and to all the founders who came along and actively engaged in the sessions. #StartUps #Founders #Networking

Next up in our Innovation Showcase series, meet Indegra Therapeutics! Founded by Richard Hatley and Simon Macdonald in 2022, Indegra Therapeutics is an integrin-based drug discovery platform company with a radically different approach to unlock effective treatments for multiple diseases, including cancer and autoimmune diseases. Its technology allows degradation of aberrant extracellular and membrane bound proteins with novel bifunctional molecules. The extracellular proteome contains many disease targets which are largely untapped and Indegra’s mission is to identify first-in-class protein degrading molecules with oral potential and high specificity for diseased tissue, ultimately leading to new medicines for patients. If you want to learn more or arrange a meeting with Richard and Simon, you can register to attend here: https://rb.gy/qc7bfg #StartUp #DrugDiscovery #ProteinDegradation #Integrins #Cancer #AutoimmuneDiseases

Introducing our next presenting company at Innovation Showcase, Octiocor! Octiocor's AutoOCT™ web-based platform is a fully automated artificial intelligence neural network-based image analysis system that was developed to identify and measure atherosclerosis from optical coherence tomography (OCT). The software interprets intravascular coronary artery images and will provide real-time decision support for cardiologists and can be used to stratify patients based on risk enabling cardiologists to make better decisions to prevent future heart attacks. To speak with Octiocor's Founder and CMO, Martin Bennett, at this year's Innovation Showcase, you can request a place here: https://rb.gy/qc7bfg #Atherosclerosis #OCT #Cardiology #AI #StartUp

Kicking off our Innovation Showcase series, we have Awen Oncology.   Focused on developing a breakthrough range of anti-cancer drugs, the Company's innovative platform homes in on previously untargeted human developmental genes that, while dormant in healthy tissues, behave unexpectedly in the early stages and progression of cancer.   Awen Oncology was spun out of Bangor University and Cardiff University and recently closed its first major funding round, bringing its total funds raised to over £1 million. You can read more about its investment here: https://rb.gy/7qk0rb   If you're interested in connecting with Dr. Ramsay McFarlane, CEO of Awen Oncology, you can register your interest to attend the Innovation Showcase here: https://rb.gy/qc7bfg   #Oncology #Innovation #StartUp #Investors

📣 Innovation Showcase 2024 is less than a month away! This year four of our portfolio companies will presenting, featuring an update on their company's progress: ⭕Awen Oncology ⭕Emm ⭕Indegra Therapeutics ⭕Octiocor They'll be joined by Cardiac-Tech Ltd, Proxximos, Verinnogen and Adora Digital Health, who will be exhibiting their technology with live demonstrations at this year's showcase. Over the next few weeks we'll be introducing each of our portfolio companies and their unique stories and innovative technologies. 📅Wednesday 13 November 📍Babraham Research Campus If you’re an investor, potential partner or part of the wider #biotech, #healthtech and #lifesciences ecosystem and would like to join us for the Innovation Showcase, please register your interest here: https://rb.gy/qc7bfg #Innovation #Startups #Investors #Cambridge

Today is #WorldMenopauseDay, a day to raise awareness of the menopause and the support systems available to women. The services offered by our portfolio company, Adora Digital Health, provide companies with the tools to support their female employees in the workplace and transform their menopause experience. Adora is led by an expert team of women's health gynaecologists, nutritionists and menopause specialists, and aims to help organisations provide better support for their female workforce using its AI-driven digital health platform. If you'd like the opportunity to speak with the Adora team, they will be exhibiting at our upcoming Innovation Showcase. Register your interest here: https://rb.gy/qc7bfg #Menopause #StartUp #DigitalHealth #Innovation

Our Innovation Showcase is now only four weeks away, so we wanted to take this opportunity to give a shout out to our fantastic sponsors, whose support is invaluable to making the event a success:   Our Gold sponsors: Venner Shipley – Intellectual Property experts and long-standing partners of Start Codon, who advise us and many of our portfolio companies on all things IP. PEM – an accountancy firm that advises businesses, non-profit organisations, individuals and families on critical areas of business, tax and wealth. Taylor Wessing – a global law firm that works closely with clients to crack complex problems, enabling ideas and aspirations to thrive.   Our Silver sponsors: Partners&. – an award-winning insurance advisory business.   And our key partners, who help make the event happen: Babraham Research Campus – who support early-stage bioscience enterprise. We’re delighted that our Showcase is taking place at their dynamic campus, where research and business come together to enable innovation. PitchWork – who support startups to create compelling content – specialising in designing and building pitch decks and presentations to help secure funding. eloquential – who help clients reach their eloquence potential through communications coaching.   To register your interest, please reach out using the following form: https://rb.gy/qc7bfg   #Innovation #StartUps #Investors #LifeSciences #Event

Next week, the Founders Growth Community are hosting the next FGC session featuring a spotlight talk from Duncan Young and Ola Zaid from AstraZeneca on 'Partnering with Pharma'. Between 11am and 4pm, we'll be hosting a 'Meet the Experts' session, which will be followed by FGC networking from 4-6pm. 📅 24 October ⌚ 11am – 6pm BST 📍 Venner Shipley offices, Cambridge Science Park This is a fantastic opportunity to hear from industry experts on how to scale a startup! The link to register can be found here: https://rb.gy/vkgqaa #LifeSciences #TechBio #Healthcare #Founder

"Can the UK's life sciences sector secure the funding it needs?" Our COO and Co-Founder, Daniel Rooke, recently contributed to an article with Susanna Stanfield and Withersworldwide to discuss concerns around the support needed to help the UK maintain its leading position in the life sciences sector. In the article, Dan offers his advice to founders to reassure investors: “The key challenges tend to be around the robustness of the underlying business (i.e., how you will make money) and people (who will you recruit, when and why). Founders need to think carefully about these issues, plan appropriately and be aware that it will likely take time to raise capital.” To read the full article, visit: https://lnkd.in/dPEEreQH #StartUps #VentureCapital #LifeSciences #Investors